Daniela M Dinulescu, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 20 | 2019 | 4750 | 1.370 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2018 | 469 | 0.710 |
Why?
|
| Neoplastic Stem Cells | 4 | 2018 | 1391 | 0.660 |
Why?
|
| Receptors, Notch | 2 | 2012 | 761 | 0.630 |
Why?
|
| 5-Methylcytosine | 1 | 2017 | 161 | 0.630 |
Why?
|
| Platinum Compounds | 2 | 2014 | 105 | 0.590 |
Why?
|
| Cisplatin | 5 | 2018 | 1663 | 0.490 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2018 | 5271 | 0.430 |
Why?
|
| Nanoparticles | 6 | 2021 | 1942 | 0.380 |
Why?
|
| Fallopian Tubes | 2 | 2019 | 175 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2016 | 3016 | 0.260 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 3469 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2019 | 8685 | 0.260 |
Why?
|
| Endometriosis | 2 | 2018 | 803 | 0.250 |
Why?
|
| Proteomics | 4 | 2019 | 3268 | 0.250 |
Why?
|
| Leukemia, Experimental | 1 | 2003 | 261 | 0.240 |
Why?
|
| Neoplasms, Experimental | 2 | 2021 | 1332 | 0.240 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2018 | 347 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 493 | 0.230 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 13754 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2000 | 1752 | 0.220 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2003 | 430 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2018 | 1160 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2017 | 3697 | 0.180 |
Why?
|
| ras Proteins | 1 | 2004 | 1117 | 0.180 |
Why?
|
| Mass Spectrometry | 3 | 2019 | 2249 | 0.180 |
Why?
|
| Mice | 27 | 2021 | 81126 | 0.170 |
Why?
|
| Hyperphagia | 1 | 1998 | 128 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 4697 | 0.170 |
Why?
|
| Doxycycline | 1 | 2019 | 312 | 0.170 |
Why?
|
| Basal Metabolism | 1 | 1998 | 163 | 0.160 |
Why?
|
| Disease Models, Animal | 5 | 2017 | 18352 | 0.160 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2017 | 108 | 0.150 |
Why?
|
| Cholesterol | 2 | 2018 | 2894 | 0.150 |
Why?
|
| Proteins | 4 | 2011 | 6166 | 0.150 |
Why?
|
| Testicular Hormones | 2 | 2006 | 191 | 0.150 |
Why?
|
| Phthalazines | 1 | 2018 | 363 | 0.150 |
Why?
|
| Dioxygenases | 1 | 2017 | 318 | 0.150 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2018 | 235 | 0.140 |
Why?
|
| Tumor Escape | 1 | 2018 | 339 | 0.140 |
Why?
|
| Carboxylesterase | 1 | 2015 | 31 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 1671 | 0.140 |
Why?
|
| Paclitaxel | 2 | 2021 | 1674 | 0.130 |
Why?
|
| Dipeptides | 1 | 2017 | 412 | 0.130 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2018 | 288 | 0.130 |
Why?
|
| Ribonuclease III | 1 | 2016 | 277 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 2907 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 1884 | 0.130 |
Why?
|
| Animals | 28 | 2021 | 170890 | 0.120 |
Why?
|
| Platinum | 2 | 2012 | 221 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2016 | 360 | 0.120 |
Why?
|
| Signal Transduction | 5 | 2018 | 23996 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 1587 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 629 | 0.120 |
Why?
|
| Cell Line, Tumor | 10 | 2021 | 16989 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 511 | 0.110 |
Why?
|
| Cell Survival | 3 | 2017 | 6133 | 0.110 |
Why?
|
| Cell Death | 2 | 2018 | 1744 | 0.110 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 2149 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2016 | 1362 | 0.100 |
Why?
|
| Proteome | 2 | 2011 | 1776 | 0.100 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 17 | 0.100 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 594 | 0.100 |
Why?
|
| Agouti Signaling Protein | 2 | 2000 | 26 | 0.100 |
Why?
|
| Peptides | 2 | 2015 | 4438 | 0.090 |
Why?
|
| Norethindrone | 1 | 2009 | 57 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 761 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 761 | 0.090 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 118 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2019 | 3680 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 2865 | 0.090 |
Why?
|
| Nanotechnology | 2 | 2012 | 709 | 0.080 |
Why?
|
| Glycoproteins | 2 | 2006 | 2318 | 0.080 |
Why?
|
| Piperazines | 1 | 2018 | 2543 | 0.080 |
Why?
|
| Apoptosis | 5 | 2017 | 10119 | 0.080 |
Why?
|
| Biosynthetic Pathways | 1 | 2008 | 141 | 0.080 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 355 | 0.080 |
Why?
|
| Glycomics | 1 | 2008 | 123 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 944 | 0.080 |
Why?
|
| HMGA2 Protein | 1 | 2007 | 128 | 0.080 |
Why?
|
| Female | 22 | 2019 | 377909 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 6564 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 4 | 2018 | 6676 | 0.070 |
Why?
|
| Databases, Protein | 1 | 2008 | 375 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 1 | 2006 | 112 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2009 | 1792 | 0.070 |
Why?
|
| Recurrence | 1 | 2017 | 8282 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 3968 | 0.070 |
Why?
|
| Receptors, Peptide | 3 | 2006 | 269 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8923 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2018 | 10802 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 9532 | 0.070 |
Why?
|
| Plasma | 1 | 2008 | 573 | 0.070 |
Why?
|
| Mice, Knockout | 6 | 2018 | 15258 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2017 | 10542 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2012 | 3022 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2017 | 4102 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2003 | 121 | 0.060 |
Why?
|
| Mice, Transgenic | 4 | 2021 | 9927 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 1190 | 0.060 |
Why?
|
| Agouti-Related Protein | 2 | 2000 | 103 | 0.060 |
Why?
|
| Disease Progression | 2 | 2017 | 13307 | 0.060 |
Why?
|
| DNA Damage | 1 | 2012 | 2470 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 3933 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2008 | 994 | 0.050 |
Why?
|
| Humans | 21 | 2021 | 717237 | 0.050 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 2000 | 25 | 0.050 |
Why?
|
| Pinocytosis | 1 | 2021 | 81 | 0.050 |
Why?
|
| Receptors, Melanocortin | 1 | 2000 | 22 | 0.050 |
Why?
|
| Receptors, Corticotropin | 1 | 2000 | 22 | 0.050 |
Why?
|
| Blood Proteins | 2 | 2019 | 1144 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2018 | 2407 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 459 | 0.050 |
Why?
|
| Desmoglein 2 | 1 | 2019 | 13 | 0.050 |
Why?
|
| Neoplasms | 3 | 2018 | 20568 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 9804 | 0.050 |
Why?
|
| Heavy Chain Disease | 1 | 2019 | 28 | 0.050 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2019 | 65 | 0.050 |
Why?
|
| Prognosis | 2 | 2017 | 29226 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2013 | 3895 | 0.050 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2019 | 46 | 0.050 |
Why?
|
| Integrases | 2 | 2013 | 553 | 0.040 |
Why?
|
| Neuropeptide Y | 1 | 1999 | 203 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2018 | 442 | 0.040 |
Why?
|
| Corticosterone | 1 | 1998 | 315 | 0.040 |
Why?
|
| Genes, p53 | 2 | 2013 | 768 | 0.040 |
Why?
|
| Thrombospondin 1 | 1 | 2019 | 253 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 394 | 0.040 |
Why?
|
| CA-125 Antigen | 1 | 2019 | 279 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3249 | 0.040 |
Why?
|
| Mutation | 2 | 2021 | 29491 | 0.040 |
Why?
|
| Kidney | 1 | 2012 | 6910 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 18738 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 5988 | 0.040 |
Why?
|
| Sarcoma | 1 | 2007 | 1878 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2018 | 567 | 0.040 |
Why?
|
| Algorithms | 1 | 2016 | 13718 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2009 | 5032 | 0.030 |
Why?
|
| Insulin | 2 | 2000 | 6691 | 0.030 |
Why?
|
| Anti-Mullerian Hormone | 2 | 2006 | 389 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 371 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1928 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 703 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6370 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 2972 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 11276 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2000 | 1292 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2013 | 218 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2845 | 0.030 |
Why?
|
| Obesity | 3 | 2000 | 12247 | 0.030 |
Why?
|
| Stem Cells | 1 | 2006 | 3597 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2019 | 8109 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2018 | 2235 | 0.030 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2012 | 120 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2018 | 3243 | 0.030 |
Why?
|
| Succinic Acid | 1 | 2012 | 88 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 718 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2011 | 12073 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 2004 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2013 | 2448 | 0.030 |
Why?
|
| Neuroendocrine Cells | 1 | 2011 | 68 | 0.030 |
Why?
|
| Actins | 1 | 2018 | 2189 | 0.030 |
Why?
|
| Nanostructures | 1 | 2016 | 592 | 0.030 |
Why?
|
| Polyenes | 1 | 2010 | 74 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 1990 | 0.020 |
Why?
|
| Leptin | 1 | 1998 | 1580 | 0.020 |
Why?
|
| alpha-MSH | 2 | 2000 | 63 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2012 | 648 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 12607 | 0.020 |
Why?
|
| Receptor, Melanocortin, Type 4 | 2 | 2000 | 126 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 2593 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2016 | 3309 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2000 | 3514 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3100 | 0.020 |
Why?
|
| Glucose | 1 | 2021 | 4303 | 0.020 |
Why?
|
| Epithelium | 1 | 2013 | 1736 | 0.020 |
Why?
|
| Gonadotropins | 1 | 2009 | 238 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 2013 | 22929 | 0.020 |
Why?
|
| Carbohydrate Sequence | 1 | 2008 | 417 | 0.020 |
Why?
|
| Fucosyltransferases | 1 | 2008 | 121 | 0.020 |
Why?
|
| Motor Activity | 1 | 1998 | 2756 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2000 | 2977 | 0.020 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2007 | 93 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2012 | 691 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 14243 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2000 | 6296 | 0.020 |
Why?
|
| Suppression, Genetic | 1 | 2007 | 206 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 481 | 0.020 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2008 | 182 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 807 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2008 | 306 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1845 | 0.020 |
Why?
|
| Genes, Retinoblastoma | 1 | 2006 | 139 | 0.020 |
Why?
|
| Verapamil | 1 | 2006 | 254 | 0.020 |
Why?
|
| Lectins | 1 | 2008 | 559 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 317 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2006 | 279 | 0.020 |
Why?
|
| Melphalan | 1 | 2006 | 383 | 0.020 |
Why?
|
| Azacitidine | 1 | 2006 | 300 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 1424 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 732 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14903 | 0.020 |
Why?
|
| CHO Cells | 1 | 2006 | 1442 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 1711 | 0.020 |
Why?
|
| Polymers | 1 | 2010 | 1630 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2008 | 1134 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 2597 | 0.010 |
Why?
|
| Estrogens | 1 | 2009 | 1529 | 0.010 |
Why?
|
| RNA Interference | 1 | 2011 | 3020 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 1120 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3615 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 21805 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5438 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 3704 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2006 | 886 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2234 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4935 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2006 | 3830 | 0.010 |
Why?
|
| Mice, Obese | 1 | 2000 | 450 | 0.010 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 1999 | 110 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2000 | 384 | 0.010 |
Why?
|
| Pro-Opiomelanocortin | 1 | 1999 | 165 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1999 | 434 | 0.010 |
Why?
|
| Rats, Long-Evans | 1 | 1999 | 405 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2017 | 62348 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 1988 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2007 | 4356 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2000 | 1159 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 39887 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 4486 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2000 | 1275 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2006 | 3694 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1999 | 1112 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 8013 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11777 | 0.010 |
Why?
|
| Middle Aged | 2 | 2019 | 215041 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9892 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 6805 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 4691 | 0.010 |
Why?
|
| Homeostasis | 1 | 2000 | 3344 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 58528 | 0.000 |
Why?
|
| Male | 3 | 2011 | 351380 | 0.000 |
Why?
|
| Time Factors | 1 | 2007 | 41095 | 0.000 |
Why?
|
| Rats | 1 | 1999 | 25091 | 0.000 |
Why?
|
| Neurons | 1 | 1999 | 9441 | 0.000 |
Why?
|
| Aged | 1 | 2011 | 162856 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 17432 | 0.000 |
Why?
|
| Adult | 1 | 2011 | 212451 | 0.000 |
Why?
|